|
1
|
Malinka T, Nebrig M, Klein F, Pratschke J,
Bahra M and Andreou A: Analysis of outcomes and predictors of
long-term survival following resection for retroperitoneal sarcoma.
BMC Surg. 19:612019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hassan I, Park SZ, Donohue JH, Nagorney
DM, Kay PA, Nasciemento AG, Schleck CD and Ilstrup DM: Operative
management of primary retroperitoneal sarcomas: A reappraisal of an
institutional experience. Ann Surg. 239:244–250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morizawa Y, Miyake M, Shimada K, Hori S,
Tatsumi Y, Nakai Y, Anai S, Tanaka N, Konishi N and Fujimoto K:
Extended resection including adjacent organs and Ki-67 labeling
index are prognostic factors in patients with retroperitoneal soft
tissue sarcomas. World J Surg Oncol. 14:432016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bonvalot S, Gaignard E, Stoeckle E, Meeus
P, Decanter G, Carrere S, Honore C, Delhorme JB, Fau M, Tzanis D,
et al: Survival benefit of the surgical management of
retroperitoneal sarcoma in a reference center: A nationwide study
of the French sarcoma group from the NetSarc database. Ann Surg
Oncol. 26:2286–2293. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tseng W, Martinez SR, Tamurian RM, Borys D
and Canter RJ: Histologic type predicts survival in patients with
retroperitoneal soft tissue sarcoma. J Surg Res. 172:123–130. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yan L, Wang Z, Cui C, Guan X, Dong B, Zhao
M, Wu J, Tian X and Hao C: Comprehensive immune characterization
and T-cell receptor repertoire heterogeneity of retroperitoneal
liposarcoma. Cancer Sci. 110:3038–3048. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tseng WW, Malu S, Zhang M, Chen J, Sim GC,
Wei W, Ingram D, Somaiah N, Lev DC, Pollock RE, et al: Analysis of
the intratumoral adaptive immune response in well differentiated
and dedifferentiated retroperitoneal liposarcoma. Sarcoma.
2015:5474602015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Keung EZ, Lazar AJ, Torres KE, Wang WL,
Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird
J, et al: Phase II study of neoadjuvant checkpoint blockade in
patients with surgically resectable undifferentiated pleomorphic
sarcoma and dedifferentiated liposarcoma. BMC Cancer. 18:9132018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Diamantis A, Baloyiannis I, Magouliotis
DE, Tolia M, Symeonidis D, Bompou E, Polymeneas G and Tepetes K:
Perioperative radiotherapy versus surgery alone for retroperitoneal
sarcomas: A systematic review and meta-analysis. Radiol Oncol.
54:14–21. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kelly CM, Antonescu CR, Bowler T, Munhoz
R, Chi P, Dickson MA, Gounder MM, Keohan ML, Movva S, Dholakia R,
et al: Objective response rate among patients with locally advanced
or metastatic sarcoma treated with talimogene laherparepvec in
combination with pembrolizumab: A phase 2 clinical trial. JAMA
Oncol. 6:402–408. 2020.(Epub ahead of print). View Article : Google Scholar
|
|
11
|
D'Angelo SP, Mahoney MR, Van Tine BA,
Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap
WD, Schwartz GK and Streicher H: Nivolumab with or without
ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two
open-label, non-comparative, randomised, phase 2 trials. Lancet
Oncol. 19:416–426. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van der Graaf WT, Blay JY, Chawla SP, Kim
DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP,
Beppu Y, et al: Pazopanib for metastatic soft-tissue sarcoma
(PALETTE): A randomised, double-blind, placebo-controlled phase 3
trial. Lancet. 379:1879–1886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wisdom AJ, Mowery YM, Riedel RF and Kirsch
DG: Rationale and emerging strategies for immune checkpoint
blockade in soft tissue sarcoma. Cancer. 124:3819–3829. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gibney GT, Weiner LM and Atkins MB:
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu Z, Jin Z, Zhang M, Tang Y, Yang G,
Yuan X, Yao J and Sun D: Prognostic value of programmed
death-ligand 1 in sarcoma: A meta-analysis. Oncotarget.
8:59570–59580. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pollack SM, He Q, Yearley JH, Emerson R,
Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, et
al: T-cell infiltration and clonality correlate with programmed
cell death protein 1 and programmed death-ligand 1 expression in
patients with soft tissue sarcomas. Cancer. 123:3291–3304. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tseng WH, Martinez SR, Tamurian RM, Chen
SL, Bold RJ and Canter RJ: Contiguous organ resection is safe in
patients with retroperitoneal sarcoma: An ACS-NSQIP analysis. J
Surg Oncol. 103:390–394. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guillou L, Coindre JM, Bonichon F, Nguyen
BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V,
Leroux A, et al: Comparative study of the national cancer institute
and French federation of cancer centers sarcoma group grading
systems in a population of 410 adult patients with soft tissue
sarcoma. J Clin Oncol. 15:350–362. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hoang K, Gao Y and Miller BJ: The
variability in surgical margin reporting in limb salvage surgery
for sarcoma. Iowa Orthop J. 35:181–186. 2015.PubMed/NCBI
|
|
20
|
Tanaka K and Ozaki T: New TNM
classification (AJCC eighth edition) of bone and soft tissue
sarcomas: JCOG bone and soft tissue tumor study group. Jpn J Clin
Oncol. 49:103–107. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miyake M, Hori S, Morizawa Y, Tatsumi Y,
Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K, et al:
CXCL1-mediated interaction of cancer cells with tumor-associated
macrophages and cancer-associated fibroblasts promotes tumor
progression in human bladder cancer. Neoplasia. 18:636–646. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Judson I, Verweij J, Gelderblom H,
Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan
J, Hohenberger P, et al: Doxorubicin alone versus intensified
doxorubicin plus ifosfamide for first-line treatment of advanced or
metastatic soft-tissue sarcoma: A randomised controlled phase 3
trial. Lancet Oncol. 15:415–423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oliveira AM, Nascimento AG, Okuno SH and
Lloyd RV: p27(kip1) protein expression correlates with survival in
myxoid and round-cell liposarcoma. J Clin Oncol. 18:2888–2893.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
She Y, Liang J, Qiu Y, Liu N, Huang X,
Zhao X and Li P: Expression of CD133 in primary retroperitoneal
leiomyosarcoma and its relationship with Ki-67. Zhonghua Yi Xue Za
Zhi. 94:1241–1244. 2014.(In Chinese). PubMed/NCBI
|
|
25
|
Ma C, Li PY, Zhang N, Sun CB, Hou L and
Liu N: Prognostic factors analysis of Ki-67, α-SMA expression in
retroperitoneal leiomyosarcoma. Zhonghua Zhong Liu Za Zhi.
40:258–263. 2018.(In Chinese). PubMed/NCBI
|
|
26
|
Rhu J, Hyun SH, Lee KH, Jo SJ, Lee KW,
Park JB and Kim SJ: Maximum standardized uptake value on
18F-fluorodeoxyglucose positron emission
tomography/computed tomography improves outcome prediction in
retroperitoneal liposarcoma. Sci Rep. 9:66052019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Daneshmandi S, Wegiel B and Seth P:
Blockade of lactate dehydrogenase-A (LDH-A) improves efficacy of
anti-programmed cell death-1 (PD-1) therapy in melanoma. Cancers
(Basel). 11:4502019. View Article : Google Scholar
|
|
28
|
Urata K, Kajihara I, Miyauchi H, Mijiddorj
T, Otsuka-Maeda S, Sakamoto R, Sawamura S, Kanemaru H,
Kanazawa-Yamada S, Makino K, et al: The Warburg effect and tumour
immune microenvironment in extramammary Paget's disease:
Overexpression of lactate dehydrogenase A correlates with immune
resistance. J Eur Acad Dermatol Venereol. 34:1715–1721. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cona MS, Lecchi M, Cresta S, Damian S, Del
Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, et al:
Combination of baseline LDH, performance status and age as
integrated algorithm to identify solid tumor patients with higher
probability of response to anti PD-1 and PD-L1 monoclonal
antibodies. Cancers (Basel). 11:2232019. View Article : Google Scholar
|
|
30
|
Kambayashi Y, Fujimura T, Hidaka T and
Aiba S: Biomarkers for predicting efficacies of anti-PD1
antibodies. Front Med (Lausanne). 6:1742019. View Article : Google Scholar : PubMed/NCBI
|
